Arcus Biosciences Targets 2026 Casdatifan Readouts, PEAK-1 Enrollment with $1B Cash Runway
Arcus plans to rapidly enroll its Phase 3 PEAK-1 study of HIF-2α inhibitor casdatifan in IO-experienced ccRCC and deliver three 2026 data readouts across monotherapy and combination cohorts, including first-line TKI-free regimens by year-end. The company holds ~$1 billion cash to fund operations through H2 2028.
1. Arcus Prioritizes PEAK-1 Enrollment and First-Line Study Launch
As Arcus Biosciences enters 2026, its top clinical priorities are the rapid enrollment of PEAK-1, the Phase 3 trial evaluating casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and the initiation of a first-line Phase 3 study guided by ongoing Phase 1 combination data. PEAK-1 enrollment is targeted for completion within 18 months, matching timelines of comparable trials, and the first-line study is slated to begin by year-end, leveraging insights from multiple ARC-20 cohorts.
2. Multiple Casdatifan Data Readouts Scheduled for 2026
Arcus expects at least three key data presentations for casdatifan during 2026. In February, updated progression-free survival and biomarker data from four monotherapy cohorts (n=121) in ARC-20 will be unveiled at a major medical conference. Mid-year, results from approximately 45 immunotherapy-experienced patients receiving casdatifan plus cabozantinib will be shared. In the second half, early-line metastatic cohorts—including casdatifan plus zimberelimab in first-line ccRCC—will report safety and efficacy outcomes, marking the first tyrosine kinase inhibitor-sparing HIF-2α regimen data in this setting.
3. Strategy to Establish Casdatifan as RCC Standard of Care
Arcus’s development plan aims to position casdatifan as a foundational treatment across ccRCC settings, addressing a potential global market opportunity exceeding $5 billion. The Phase 3 PEAK-1 trial targets immunotherapy-experienced patients with a cabozantinib backbone, while first-line efforts focus on TKI-free regimens designed to reduce early progression and delay TKI-related toxicities. Planned cohorts include two additional casdatifan plus anti-PD-1 combinations and a collaboration with AstraZeneca on casdatifan plus volrustomig, all feeding into a registrational first-line study by year-end.
4. Advancement of Inflammation and Immunology Pipeline into the Clinic
Beyond oncology, Arcus will advance its lead inflammation asset—a potent oral MRGPRX2 antagonist for atopic dermatitis and chronic spontaneous urticaria—into clinical development in 2026. The molecule offers high target coverage at low doses to minimize toxicity. Later in the year or early 2027, an oral TNF inhibitor for rheumatoid arthritis, psoriasis and ulcerative colitis is expected to enter the clinic. These programs leverage Arcus’s small-molecule expertise against targets traditionally addressed by injectable biologics.